IL−1 blockade is also well−established in treating autoinflammatory conditions such as cryopyrin-associated periodic syndromes (CAPS), familial Mediterranean fever (FMF), and rheumatoid arthritis (150, 151). Here, IL1B is linked to cryopyrin-associated periodic syndrome.